It was earning season. brutal. At the smaller end of the market, three ASX small cap winners Stands out providing encouraging numbers.
The volatility of the reporting season increased again in February.
Volatility, though, is a well-worn path for the short end of the market. With thin liquidity and low analyst coverage, the market can rerate or derate a company in a single session, regardless of the underlying outcome. In an inflation-troubled market, monitoring CPI or interest rate chatter makes small caps vulnerable. Often considered higher risk, when rates are rising, investors look for larger, “safer” assets (you know, like CSL – down ~20% since reporting). Through the ups and downs, ultimately, these are businesses, albeit smaller than your usual headline grabbers, and they are performing. We take a look at 3 ASX small-cap winners that may be worth further digging.
Energy One’s recurring revenue and operating leverage
ENERGY ONE LIMITED (ASX: EOL) half-yearly report delivered a strong result.
We’ve written about Energy One here before.
Energy One reported revenue of $34.8 million (+21%) and profit after tax of $4.0 million (+61%), reflecting strong scale. The business is now generating 90%+ recurring revenue.
The market craves recurring income and the perceived certainty that comes with it. Energy One sits in the center of the small-mid cap band at around $450m market cap, making it small enough to really grow in market cap, and large enough to fund.
The Smart Parking measure appears in the P&L.
Smart Parking (ASX: SPZ) has been building a bigger, more global platform for several years now.
The $445 million market cap listed parking inspector collects parking breach notices (PBN’s) using its camera technology for private parking bays. Its results for the first half of 2026 showed continued growth. More sites and US acquisitions boosted revenue to $62.6m (+96%) and adjusted EBITDA to $15.6m (+85%).
The flat growth of PBN in the UK is noteworthy. Smart parking cited cost of living pressures, but something to watch going forward to make sure it’s a one-off and not a pattern.
Demand for Cogstate is growing.
Cogstate Ltd (ASX: CGS) partners with drug developers to help measure clinical trial endpoint data for accuracy, with a focus on the central nervous system.
Revenues are growing to $26.9 million (+12%) while operating expenses are down 9%, which is exactly what you want to see as the business scales and costs fall as a percentage of revenue. The only “messy” bit was gross margin, which fell to 52.8% from 61.4% last year. Management says the margin squeeze is temporary, a trade-off to win market share, targeting 56-59% in the second half and 60%+ long term.
At a market cap of $400 million, Cogstate deserves a spot on your small mid-cap watch list.
The last word
With each earnings season that passes, the reaction to results feels more volatile than ever.
For small caps, every 6 months, you get a clear picture of the company’s performance. Each of the above companies shined in different ways, but all delivered more revenue and profit growth, delivered at the scale, that investors wanted. Whether the company is growing.
In a volatile reporting period, this combination is often what separates good results from a company for which investors are willing to pay more.
